Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Pfizer Inc.
67 Articles Available
1
3
Can't find what you're looking for? Try our
advanced search
.
Recall
Pfizer Inc. Issues A Voluntary Nationwide Recall For 2 Lots of RELPAX® Due to Potential Microbiological Contamination of Non-Sterile Product
PR-M08-19-NI-048
M&A
GSK Completes Transaction with Pfizer to Form New Consumer Healthcare Joint Venture
PR-M08-19-NI-009
M&A
Pfizer Completes Acquisition of Array Biopharma
PR-M07-19-NI-080
Generics
FDA Approves First Generics of Lyrica
PR-M07-19-NI-060
Drug Access
British Lung Cancer Patients Will Get Access to Pfizer’s Vizimpro
PAO-M07-19-NI-020
Clinical Results
Positive Results for Colon Cancer Drug Drove Pfizer’s Purchase of Array BioPharma
PAO-M07-19-NI-017
Leadership
Gottlieb Joins Pfizer Board of Directors
PAO-M07-19-NI-013
Clinical Data
Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD)
PR-M07-19-NI-017
M&A
Pfizer Acquires Array BioPharma for $11.4 Billion
PAO-M06-19-NI-018
M&A
Pfizer to Acquire Array BioPharma
PR-M06-19-NI-027
Pfizer Announces Positive Top-Line Results from Phase 3 Study in Patients with Moderate to Severe Atopic Dermatitis
PR-M05-19-NI-055
Drug Approval
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
PR-M05-19-NI-036
Positive Opinion
Pfizer Receives Positive CHMP Opinion for TALZENNA®(talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer
PR-M04-19-NI-086
Consumer Healthcare
GSK and Pfizer’s Combined Consumer Healthcare Business Will Focus on the U.S. and China
PAO-M04-19-NI-016
Announcement
Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
PR-M03-19-NI-062
Licensing
Pfizer Licenses AnTolRx Type 1 Diabetes Candidate
PAO-M03-19-NI-021
Oncology
Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer
PR-M03-19-NI-005
Licensing Agreement
Pfizer to License AbbVie’s Humira IP
PAO-M12-18-NI-006
Biosimilars
Pfizer’s Rituximab Biosimilar Achieves Positive Study Results
PAO-M12-18-NI-001
FDA Approval
US FDA Approves Third Pfizer Cancer Drug in Two Months
PAO-M11-18-NI-014
New Partnership
Neuroscience Company Created by Bain Capital and Pfizer
PAO-M11-18-NI-004
Breakthrough Therapy
Pfizer Granted FDA Breakthrough Therapy Designation for 20-valent Pneumococcal Conjugate Vaccine
PR-M10-18-NI-001
Collaboration
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
PR-M09-18-NI-052
Marketing Authorization
XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis
PR-M08-18-NI-024
1
3
»
